References

1. Handler JA, Ghezzi KT. General ophthalmologic examination. Emerg Med Clin North Am 1995;13(3):521-538.

2. Harlan JB Jr, Pieramici DJ. Evaluation of patients with ocular trauma. Ophthalmol Clin North Am 2002;15(2):153-161.

3. Wilson SA, Last A. Management of corneal abrasions. Am Fam Physician 2004;70(1):123-128.

4. Deutsch TA. Ocular emergencies in childhood. Pediatrician 1990;17(3):173-176.

5. McEvoy GK, ed. AHFS drug information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2008.

6. Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol 2005;139(4):730-733.

7. Garcia GE. Management of ocular emergencies and urgent eye problems. Am Fam Physician 1996;53(2):565-574.

8. Barish RA, Naradzay JF. Ophthalmologic therapeutics. Emerg Med Clin North Am 1995;13(3):649-667.

9. LaVene D, Halpern J, Jagoda A. Loss of vision. Emerg Med Clin North Am 1995;13(3):539-560.

10. Donahue SP, Khoury JM, Kowalski RP. Common ocular infections. A prescriber's guide. Drugs 1996;52(4):526-540.

11. Leibowitz HM. The red eye. N Engl J Med 2000;343(5):345-351.

Thielen TL, Castle SS, Terry JE. Anterior ocular infections: An overview of pathophysiology and treatment. Ann Pharmacother 2000;34(2):235-246.

Baum J. Infections of the eye. Clin Infect Dis 1995;21(3):479-486; quiz 487-488.

Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998;57(4):735-746.

McEvoy GK, ed. AHFS drug information Essentials 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2008.

Inspire Pharmaceuticals Inc. Azasite (azithromycin 1%) ophthalmic solution prescribing information. Durham NC; 2007 Jul.

Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65(2):215-228.

Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr Drug Targets Inflamm Allergy 2002;1(2):167-180.

Bielory L. Ocular allergy guidelines: A practical treatment algorithm. Drugs 2002;62(11):1611-1634.

Titi JM. A critical look at ocular allergy drugs. Am Fam Physician 1996;53(8):2637-2642, 2645-2646.

Rapuano CJ, Feder RS, Jones MR, et al. American Academy of Ophthalmology. Bacterial keratitis, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2005.

Chew EY, Benson WE, Boldt, HC, et al. American Academy of Ophthalmology. Age-related macular degeneration, preferred practice pattern. San Francisco: American Academy of Ophthalmology; 2006.

Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122(4):564-572.

Hyman L, Neborsky R. Risk factors for age-related macular degeneration: An update. Curr Opin Ophthalmol 2002;13(3):171-175.

Arnold J, Sarks S. Age related macular degeneration. Clin Evid 2004(11):819-834.

Comer GM, Ciulla TA, Criswell MH, Tolentino M. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004;21(15):967-992.

Novartis. Visudyne (verteporfin) for injection prescribing information. East Hanover, NJ; 2004.

28. Ferris FL, Chew EY, Sperduto R for the age-related eye disease study group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001;119(10):1439-1452.

29. Mares JA, La Rowe TL, Blodi BA. Doctor, what vitamins should I take for my eyes? Arch Ophthalmol 2004;122(4):628-635.

30. Eyetech Pharmaceuticals, Inc. Macugen (pegaptanib sodium) injection product information. New York; 2004.

31. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351(27):2805-2816.

32. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004;15(4):299-304.

33. Matoba AY, Harris DJ, Meisler DM, et al. American Academy of Ophthalmology. Dry eye syndrome, preferred practice pattern; San Francisco: American Academy of Ophthalmology; 2003.

34. Allergan, Inc. Restasis (cyclosporine 0.05%) ophthalmic emulsion prescribing information. Irvine, CA; 2004.

35. Roxane Laboratories. Pilocarpine hydrochloride tablets prescribing information. Columbus, OH; 2007 Sept.

36. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102(4):551-553.

37. Roy FH. Ocular Differential Diagnosis. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.

38. Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004;15(6):541-548.

39. Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol 1999;10(6):438-446.

SECTION 13 DERMATOLOGIC DISORDERS

Allergic To Everything

Allergic To Everything

The human body And Todays chemical infested world. Here is a news flash You are not allergic to pollen, pet dander, or whatever it is that makes your body revolt Rather, your body just can not handle that one thing, what ever it is, anymore, due to the massive barrage of toxic chemicals you and everyone else are ingesting every single day.

Get My Free Audio and Ebook


Post a comment